Evidence map›Paper›PMID 27935602›Full record

SynthesisEye (London, England)2017

Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review.

N Brito-García, T Del Pino-Sedeño, M M Trujillo-Martín, R M Coco, E Rodríguez de la Rúa, I Del Cura-González, P Serrano-Aguilar

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Eye (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. The Role of Vitamin A in Retinal Diseases.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Feed the Eye to Heal the Eye.Journal of current ophthalmology
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

N Brito-GarcíaFundación Canaria de Investigación Sanitaria (FUNCANIS), Islas Canarias, Spain.
T Del Pino-SedeñoFundación Canaria para el Avance de la Biomedicina y la Biotecnología (BIOAVANCE), Universidad de La Laguna, Islas Canarias, Spain.
M M Trujillo-MartínFundación Canaria de Investigación Sanitaria (FUNCANIS), Islas Canarias, Spain.
R M CocoInstitute of Applied Ophthalmo-Biology (IOBA), University of Valladolid, Valladolid, Spain.
E Rodríguez de la RúaRTIC patología ocular del envejecimiento, calidad visual y calidad de vida (OFTARED), Instituto de Salud Carlos III, Madrid, Spain.
I Del Cura-GonzálezCentro de Investigaciones Biomédicas de Canarias (CIBICAN), Universidad de La Laguna, Islas Canarias, Spain.
P Serrano-AguilarRed de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain.
Fundación Canaria de Investigación Sanitaria · ESCentro de Investigación Biomédica en Red · ESInstituto de Salud Carlos III · ESMadrid Health Service · ESUniversidad de La Laguna · ESUniversidad de Valladolid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hereditary retinal dystrophies (HRDs) are a group of genetically determined disorders that result in loss of the visual function. There is a lack of standard pharmacological treatments or widely accepted nutritional recommendations. The objective of this review is to summarise the scientific evidence on the effectiveness and safety of nutritional supplements for the treatment of HRDs. We conducted a scientific literature search on Medline and PreMedline, EMBASE, SCI-EXPANDED, SSCI, and The Cochrane Library up to August 2014. Experimental, quasi-experimental and controlled observational studies were selected. Eight studies were ultimately included, seven on retinitis pigmentosa (RP) and one on Best disease. Vitamin A, vitamin E, docosahexaenoic acid (DHA), lutein and β-carotene were assessed. A 15 000 IU daily dose of vitamin A was reported to have shown a small protective effect on the progression of RP, as was the use of the carotenoids lutein and β-carotene. Different DHA doses has no effect on RP or Best disease. No supplement showed severe adverse effects in the selected studies although strong evidence of toxicity exists for high doses of vitamin A and β-carotene in certain populations. The selected studies concluded that there may be a small beneficial effect of vitamin A, lutein and β-carotene on the progression of RP. The limited evidence available indicates some well-designed additional studies on combined supplements strategies may achieve more robust conclusions. Moreover, the scarcity of evidence available on the treatment of HRD other than RP with nutritional supplements supports the need for further research efforts.

Indexed as

Dietary SupplementsAntioxidantsCarotenoidsDisease ProgressionElectroretinographyHumansRetinal DystrophiesVisual AcuityVisual PerceptionVitaminsAntioxidantsCarotenoidsVitamins

Identifiers

PMID27935602
PMCPMC5306468
OpenAlexW2560101831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.